Enanta Pharmaceuticals, Inc.

NasdaqGS:ENTA Rapport sur les actions

Capitalisation boursière : US$197.9m

Enanta Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Le PDG Enanta Pharmaceuticals est Jay Luly, nommé en Jul2003, a un mandat de 21.33 ans. La rémunération annuelle totale est $ 7.86M, composée du salaire de 9.6% et des bonus 90.4%, y compris les actions et options de la société. détient directement 3.51% des actions de la société, d'une valeur de $ 6.95M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.9 ans et 8 ans.

Informations clés

Jay Luly

Directeur général

US$7.9m

Rémunération totale

Pourcentage du salaire du PDG9.6%
Durée du mandat du directeur général21.3yrs
Propriété du PDG3.5%
Durée moyenne d'occupation des postes de direction3.9yrs
Durée moyenne du mandat des membres du conseil d'administration8yrs

Mises à jour récentes de la gestion

Recent updates

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

Oct 05
Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Aug 08
Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Jul 24
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Jun 19
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

May 09
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Mar 05
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Aug 13
Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Feb 24
We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Feb 08
Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25
Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Oct 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Enanta starts mid-stage trial of EDP-938 for RSV infection

Oct 03

Enanta Pharma FQ3 2022 Earnings Preview

Aug 07

Enanta potential COVID drug shows safety in healthy people in early-stage trial

Jul 29

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Jul 04
Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Enanta: Slow Drip

May 17

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Feb 04
Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Nov 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Analyse de la rémunération des PDG

Comment la rémunération de Jay Luly a-t-elle évolué par rapport aux bénéfices de Enanta Pharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$115m

Mar 31 2024n/an/a

-US$132m

Dec 31 2023n/an/a

-US$138m

Sep 30 2023US$8mUS$755k

-US$134m

Jun 30 2023n/an/a

-US$132m

Mar 31 2023n/an/a

-US$125m

Dec 31 2022n/an/a

-US$121m

Sep 30 2022US$7mUS$725k

-US$122m

Jun 30 2022n/an/a

-US$120m

Mar 31 2022n/an/a

-US$112m

Dec 31 2021n/an/a

-US$101m

Sep 30 2021US$5mUS$693k

-US$79m

Jun 30 2021n/an/a

-US$84m

Mar 31 2021n/an/a

-US$74m

Dec 31 2020n/an/a

-US$58m

Sep 30 2020US$5mUS$667k

-US$36m

Jun 30 2020n/an/a

US$2m

Mar 31 2020n/an/a

US$24m

Dec 31 2019n/an/a

US$34m

Sep 30 2019US$4mUS$642k

US$46m

Jun 30 2019n/an/a

US$65m

Mar 31 2019n/an/a

US$78m

Dec 31 2018n/an/a

US$86m

Sep 30 2018US$4mUS$611k

US$72m

Rémunération vs marché: La rémunération totale de Jay ($USD 7.86M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.46M ).

Rémunération et revenus: La rémunération de Jay a augmenté alors que l'entreprise n'est pas rentable.


PDG

Jay Luly (68 yo)

21.3yrs

Titularisation

US$7,856,698

Compensation

Dr. Jay R. Luly, Ph.D. has been the Chief Executive Officer, President and Director of Enanta Pharmaceuticals, Inc. since July 2003. Dr. Luly joined Enanta in July 2003. Previously he was employed at Oxfor...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Jay Luly
President21.3yrsUS$7.86m3.51%
$ 6.9m
Paul Mellett
Chief Financial & Administrative Officer21.2yrsUS$2.85m0.35%
$ 699.1k
Yat Or
Senior VP of Research & Development and Chief Scientific Officer25yrsUS$2.97m1.66%
$ 3.3m
Nathaniel Gardiner
Consultantless than a yearUS$2.86m0.43%
$ 845.9k
Brendan Luu
Chief Business Officer3.8yrsUS$2.58m0.10%
$ 203.7k
Jennifer Viera
Senior Director of Investor Relations & Corporate Communicationsno datapas de donnéespas de données
Matthew Kowalsky
Chief Legal Officerless than a yearpas de donnéespas de données
Tara Kieffer
Chief Product Strategy Officer3.9yrsUS$2.10m0.071%
$ 140.7k
Scott Rottinghaus
Senior VP & Chief Medical Officer2.3yrsUS$4.84m0.017%
$ 33.0k

3.9yrs

Durée moyenne de l'emploi

59.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de ENTA est considérée comme expérimentée (ancienneté moyenne 3.9 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Jay Luly
President21.3yrsUS$7.86m3.51%
$ 6.9m
Mark Foletta
Independent Director4.4yrsUS$331.41k0%
$ 0
Bruce Leonard Carter
Independent Non-Executive Chairman11yrsUS$353.91k0%
$ 0
Terry Vance
Independent Director13.4yrsUS$333.91k0.027%
$ 54.2k
Kristine Peterson
Independent Director7.2yrsUS$326.41k0%
$ 0
Yujiro Hata
Independent Director3.3yrsUS$318.91k0%
$ 0
Lesley Russell
Independent Director8yrsUS$321.41k0%
$ 0

8.0yrs

Durée moyenne de l'emploi

65yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de ENTA sont considérés comme expérimentés (ancienneté moyenne 8 ans).